David Hutton

Dec 11, 2024 | ophthalmologytimes.com | David Hutton

Bausch + Lomb Corp. today announced that an affiliate has acquired Elios Vision Inc., developer of the ELIOS procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser.

Dec 10, 2024 | ophthalmologytimes.com | David Hutton

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discussed interleukin-6 (IL-6), a signaling molecule crucial in regulating the immune system and its role in autoimmune diseases, particularly thyroid eye disease (TED). IL-6 influences T cells, B cells, and inflammatory cells, driving immune processes that can be beneficial in infections but harmful in autoimmune conditions.

Dec 10, 2024 | ophthalmologytimes.com | David Hutton

ViaLase Inc. announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will investigate the aqueous outflow dynamics of ViaLase’s novel laser procedure, using Moran's advanced iPerfusion technology. The ViaLase laser procedure delivers precise femtosecond laser pulses, guided by micron-accurate imaging, to create apertures through the trabecular meshwork (TM) and into Schlemm’s canal.

Dec 10, 2024 | ophthalmologytimes.com | Sydney Crago |Martin Harp |Sheryl Stevenson |David Hutton

CommentaryVideoDecember 10, 2024Author(s):,In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity.

Dec 10, 2024 | optometrytimes.com | David Hutton

Galimedix Therapeutics Inc. announced the initiation of dosing in its phase 1 clinical trial evaluating oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy. The phase 1 study aims to enroll up to 40 healthy volunteers in the single ascending dose (SAD) cohort and 32 participants in the multiple ascending dose (MAD) cohort.